Position
EntryPoint Capital, LLC in Arbutus Biopharma Corp
Back to the book · All holders of ABUS
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark −$23.4K$4.81 → $4.50
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 75.6K | $363.7K | — | — | — | 0.1% |
| Q1 2026 | 110.1K | $495.6K | $4.50 | −$23.4K | $155.3K | 0.1% |